Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
February 11, 2020
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone, and welcome to the conference call on Palatin Technologies' operating results for the second quarter of fiscal year 2020. Please note that this call is being recorded. Before we get into our remarks, I want to point out that any statements Palatin makes that aren't historical facts could be forward-looking statements. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated because of various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. When you evaluate these forward-looking statements and Palatin's prospects, please weigh those risks and uncertainties carefully. I'll now hand the call over to today's host, Dr. Carl Spana, Palatin Technologies' President and Chief Executive Officer. Sir, please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and welcome to the Palatin Technologies call covering the second quarter of fiscal year 2020. This is Dr. Carl Spana, CEO and President of Palatin. Joining me today is Steve Wills, Palatin's Executive Vice President, Chief Financial Officer and Chief Operating Officer. During this call, we'll share financial and operating updates. I'll now hand things over to Steve, who will give the financial updates. Steve?
Steve Willis
unknownThanks, Carl, and good morning to all of you. Turning to Palatin's quarter that closed on December 31, 2019, the financial and operational highlights include, with respect to Vyleesi, the first as-needed therapy cleared for premenopausal women suffering from acquired generalized Hypoactive Sexual Desire Disorder, or HSDD. On January 9, 2020, AMAG said that following a strategic review it would divest Vyleesi along with Intrarosa, another women's healthcare product. AMAG noted it has already gotten preliminary expressions of interest in those assets. Per the Vyleesi license agreement, AMAG is contractually required to make commercially reasonable efforts to commercialize Vyleesi. Should AMAG materially breach that duty and not cure the breach, Palatin might potentially hold the right to end the license agreement and compel AMAG to assign and transfer its Vyleesi rights to Palatin. If AMAG assigned its Vyleesi license to a party other than Palatin, that assignee would have to expressly consent to be bound by the Vyleesi license agreement between AMAG and Palatin. As for Vyleesi collaborations, we are pushing forward with talks covering territories beyond the currently licensed ones of North America, China and Korea, and we expect to sign multiple agreements during calendar year 2020. Vyleesi is licensed to Fosun Pharma in China and to Kwandong Pharmaceuticals in South Korea.
Steve Willis
unknownIn terms of Vyleesi, both companies are moving it through the regulatory process in their respective territories, and that involves running certain clinical studies in those territories before they file for market approval. Regarding Vyleesi and our other development programs, Dr Spana will go into more detail on those during his part of the presentation. Moving to financial highlights: for the quarter ended December 31, 2019, on the revenue side for the quarter ended December 31, 2019, we recognized $20,610 as revenue along with reimbursement of shared Vyleesi costs tied to our license agreement with AMAG. No revenues were recorded in the three months ended December 31, 2018. On operating expenses, total operating expenses for the quarter ended December 31, 2019 came to 5.7 million, versus 5.1 million in the comparable quarter of 2018. The rise in operating expenses was primarily attributable to the final payment of $625,000 made in connection with the mutually agreed upon termination of our engagement agreement with Greenhill & Company LLC. On other income, total other income was $397,480 for the quarter ended December 31, 2019, compared with total other income of $7,871 in the comparable quarter of 2018. That difference is mainly due to higher investment income on our cash and cash equivalents.
Steve Willis
unknownOn the cash position and working capital side, cash, cash equivalents and accounts receivable stood at 91.6 million as of December 31, 2019, versus 96.8 million on September 30, 2019, and 103.8 million on June 30, 2019. Current liabilities came in at 1.4 million at December 31, 2019, compared with 1.9 million at September 30, 2019, and 4.2 million at June 30, 2019. With roughly just under 92 million in cash and cash equivalents at December 31, 2019, we have enough funding to carry our planned programs through calendar 2020 and at least calendar 2021. With that, I'll hand the call back to Carl.
Carl Spana
executiveThanks, Steve. I'll begin the operational update by discussing Vyleesi — the first-in-class melanocortin agonist and the sole as-needed product the FDA has approved for treating Hypoactive Sexual Desire Disorder, or HSDD. It gives premenopausal women a safe and effective as-needed treatment. As all of you surely know, in January 2020, AMAG Pharmaceuticals announced that, following a strategic review, it will divest Vyleesi, which it licenses exclusively from Palatin for North America. AMAG's planned divestiture of Vyleesi rests on its strategy change and on the uncertain commercial viability of Makena, its preterm or premature birth medication — not on Vyleesi's value and commercial potential. With AMAG divesting Vyleesi, we will have a new North American partner for the product. As Steve mentioned earlier on this call, we are taking every appropriate step to protect our rights under the Vyleesi license agreement and to ensure Vyleesi's value stays intact throughout this process. That said, we understand why AMAG is divesting Vyleesi, and we will support its efforts to ensure that a new North American Vyleesi partner is committed to a genuinely robust commercialization program capable of realizing Vyleesi's potential.
Carl Spana
executiveBack in late September 2019, AMAG launched Vyleesi across the country, with two specialty pharmacies handling prescription processing. The commercial launch of Vyleesi is still underway under AMAG's leadership. Drawing on early launch figures and further data we've gathered, our conviction remains strong that Vyleesi holds meaningful commercial potential. Beyond North America, we're collaborating with Fosun Pharma, our partner in China, and Kwangdong Pharmaceuticals, our partner in South Korea, to push Vyleesi development forward in those markets toward regulatory submissions. Following the FDA's approval of Vyleesi, commercial interest in unlicensed territories keeps expanding, and we're now actively talking with several prospective partners that are assessing Vyleesi across all available territories. Our view is that AMAG's divestiture of Vyleesi won't significantly affect our capacity to license Vyleesi in other territories. We're working to pinpoint the strongest Vyleesi partners as we execute further Vyleesi licensing and commercialization agreements. As Steve said, we aim to have Vyleesi partnerships completed for all major full territories by the close of calendar year 2020. We believe this Vyleesi licensee approach will maximize the return on our investment and let us concentrate our resources on our pipeline programs.
Carl Spana
executiveContinuing, during the quarter just ended, we kept moving our pipeline programs forward in autoimmune and inflammatory diseases. Those programs rest on our research efforts and the basic science of the melanocortin system when it comes to regulating and resolving inflammation in average immune responses. Our particular interest lies in targeting the melanocortin system for the treatment of ocular diseases. We currently have 3 active ocular programs, covering dry eye disease, diabetic retinopathy and non-infectious uveitis. We're excited to share that our PL9643 dry program is entering clinical trials. A Phase 2 study of the PL9643 ophthalmic solution — which simply means topical eye drops — in dry eye disease will start screening patients later this week. Dry disease, also called keratoconjunctivitis sicca, affects the cornea, the conjunctiva of the eye, producing irritation, redness, pain and blurred vision; its causes vary, and we believe that by activating the melanocortin system locally, PL9643 will lessen the inflammation underlying many aspects of dry eye disease. In brief, the Phase 2 study is randomized and placebo controlled, designed to evaluate efficacy and safety of the PL9643 ophthalmic solution versus placebo in patients who have dry eye disease. This study aims to enroll 150 patients across two arms.
Carl Spana
executivePatient selection involves a screening period of two weeks, and those randomized are expected to undergo 12 weeks of treatment. The primary endpoints consist of inferior corneal fluorescein staining, assessed at day 85 both before and after a controlled adverse environment challenge, along with ocular discomfort measured at day 85. Beyond these, the study includes numerous secondary and exploratory endpoints. Results from this study should become available during the fourth quarter of 2020, and further specifics about the trial will be posted on the clinical trials.gov website. Should the study succeed, it would generate the data needed to move PL9643 ophthalmic solution forward into pivotal Phase 3 studies. Treatments for dry eye disease represent a meaningful commercial opportunity, with annual sales exceeding 2 billion and ongoing growth driven by patient demographics. We believe that the potentially favorable efficacy, tolerability, and safety profile of 9643 could enable considerable penetration of the dry eye market. Additional programs in our ocular pipeline include PL-8331, a melanocortin-1 and 5 agonist being developed for diabetic retinopathy, and subcutaneous PL-8177, a selected MCR melanocortin-1 receptor agonist intended for non-infectious uveitis. In preclinical animal disease models, both compounds have demonstrated significant efficacy and the potential to influence the underlying disease process. For PL-8331, we are carrying out the preclinical research and development work necessary to file an IND and initiate clinical studies, with the goal of starting and completing a Phase 2 proof of principle study in 2021.
Carl Spana
executiveRegarding PL-8177, which has received orphan drug designation for treating non-infectious uveitis, we have additionally finished all work required after the IND and begun clinical studies. We plan to run a Phase 2 clinical study in non-infectious uveitis in 2021, once we have reviewed the data from the diabetic retinopathy study. Beyond our ocular pipeline programs, we have created an oral colon release formulation of PL-8177 for treating ulcerative colitis and other inflammatory bowel diseases. Two Phase 1 PL-8177 clinical trials have been completed by us. The first was a combined single ascending and multiple ascending dose study evaluating <<inaudible>> the systemic safety of subcutaneously administered 8177. The second study assessed the pharmacokinetics and safety of the oral colon delivery formulation of PL-8177. We are now positioned to move into a Phase 2 proof of principle clinical study in ulcerative colitis using the oral colon release formulation. Those studies are anticipated to begin in mid calendar 2020, with data read out in mid calendar 2021. We also have two programs backed by our research on the natriuretic peptide system; PL-3944, a selective natriuretic peptide receptor A agonist, is scheduled to begin a phase two trial sponsored by the American Heart Association, which will be conducted by two major medical academic research centers.
Carl Spana
executiveRegulatory approvals for the trial have been obtained, and we expect the study to start in 2020. While it remains preclinical, we're enthusiastic about our compound PL-5028, a dual natriuretic peptide A and C receptor agonist that has potential for treating cardiovascular and fibrotic diseases. Preclinical work in liver fibrosis and pulmonary fibrosis was finished last year, and PL-5028 has yielded encouraging results. Under our development plan for 5028, we will complete further preclinical FC studies in fibrotic disease models and, if those are positive, kick off the preclinical activities needed to file an IND and start clinical studies. More details about our programs are available on our website, www.palatin.com. To wrap up, our 92 million in cash as of December 31, 2019, together with the expanding revenue stream from new Vyleesi licenses, sales and milestones, leaves us with a strong current balance sheet to support advancing our exciting pipeline programs. We see the approval of Vyleesi as validation of the melanocortin system as a drug development target, and the potential of our melanocortin autoimmune and inflammatory development programs excites us. During calendar year 2020, we will focus on the following, taking the proper steps to protect our rights under the Vyleesi North American license agreement so that the value of Vyleesi stays intact and keeps growing.
Carl Spana
executiveWe'll keep being opportunistic and flexible as the divestiture process moves forward, with the goal that whoever ultimately licenses the North American rights to Vyleesi is dedicated to robust commercialization of the product. We'll keep supporting Fosun Pharma's and Kwangdong Pharmaceuticals' Vyleesi development work as they move Vyleesi toward regulatory submissions in their territories, and we'll work to execute additional Vyleesi commercialization agreements. We'll also keep advancing our pipeline programs: starting the Phase 2 PL-9643 dry eye clinical study, completing the final activities to begin the Phase 2 PL-8177 in ulcerative colitis, and moving PL-8831 toward an IND filing in diabetic retinopathy. Thank you. We'll now open the call for questions.
Operator
operatorJohn Newman has our first question.
John Newman
analystI just wanted to ask about Vyleesi. I'm curious, roughly speaking, whether you and AMAG have any kind of timeframe in mind for finding a new partner for <<inaudible>> the specific items laid out in the agreement you signed, or if the timing is different — I was just curious.
Steve Willis
unknownAbsolutely. Thanks for asking, John. This is Steve. Let me make it clear: this process belongs to AMAG. As the North American licensee, they've made a decision based on strategic factors to divest Vyleesi and Intrarosa. AMAG has said publicly that they're proceeding with the divestiture process, and they hope to have something completed, or at least be in advanced discussions, by the end of the first quarter or sometime in the second quarter of this calendar year. We support that process. Our relationship with AMAG is very good, and should Palatin be brought into the process for discussions with potential partners, we'll cooperate accordingly. We want to make sure that if AMAG is no longer the North American licensee, then the next owner of Vyleesi — the licensee for North America — we talk about commitment, but capabilities matter too, right? You want a company that's committed to advancing this female health care product, but that also has the capabilities to move it forward. That way the value of <<inaudible>> of Vyleesi can be achieved. Since this is a 12/31 year-end and we're actually a fiscal June 30, we hope and anticipate that AMAG won't be holding their conference call until early March.
Steve Willis
unknownSo our expectation is that they'll provide considerably more detail on the divestiture process at that point.
John Newman
analystAll right, that's helpful. And to the best of your knowledge, the complete promotional efforts and backing for Vyleesi are still up and running and in effect — would that be a fair statement?
Steve Willis
unknownWell, I mean, that's — I think that's a statement. That's a question AMAG can answer much better from an accuracy standpoint. We know they aren't proceeding with the product as though they owned it. And that was said at the JPMorgan conference, which isn't a surprise. Moving forward on a product you're going to divest is different than moving forward on a program you're investing in for the greatest value <<inaudible>>. So we understand where that sits in the process. And again, I would anticipate and expect that we'll get a bit more granularity regarding the divestiture process on the early March AMAG conference call.
John Newman
analystAlright, that's great. Thanks a lot.
Operator
operatorJoe Pantginis from HC Wainwright has our next question.
Joe Pantginis
analystJust want to circle back on Vyleesi, if that's alright. You brought it up near the start of your prepared remarks — something about AMAG being obligated to keep this process moving in good faith under the contract. So does that contract contain any stipulations about actual timing for them to divest the product, and what potential recourse would you have that would, I suppose, define a breach of contract?
Carl Spana
executiveSure. There isn't any particular schedule for a divestiture. Speaking practically, though, I believe getting it done as fast as they can serves their own interests. They've got a full sales force; to the best of our knowledge, Joe, none of their sales force people have been let go yet. And we know those sales force people are out there detailing the product to doctors, as they're obligated to do. Eventually, to achieve the cost savings they believe a divestiture could deliver, they might need to scale back. Once they start doing that, their position becomes more difficult when it comes to the relationship with Palatin and the possible contract we have. So while no direct timeline exists, my expectation is that they'll move on it about as fast as possible, since that's what they want.
Joe Pantginis
analystNo, that's clear. Thanks. And since you brought up Fosun and Kwangdong, could you maybe walk us through a bit more on where each of those territories currently stands when it comes to getting Vyleesi to market?
Carl Spana
executiveYes, certainly. In both of those nations, there have been several rounds of talks with the regulators, and we took part in each of them. Those authorities have asked for a few extra, smaller clinical trials, mainly to examine how the product behaves pharmacokinetically across different patient groups — which is quite standard practice in those markets. The protocols for those trials have already been filed, and we expect the studies to get underway during the first half of this year. They ought to be finished and wrapped up prior to year-end, with filings to follow soon after.
Operator
operatorMichael Higgins has our next question.
Michael Higgins
analystA couple of things on Vyleesi, if I may. Could you give us an update on whether this remains accurate? I think previously you said that from <<inaudible>> milestones really in 21, from Fosun and Kwangdong, of approximately 7.5 million and 3 million. Should we still be looking forward to those numbers on that timing?
Steve Willis
unknownSteve here. Michael, I appreciate the question. Those figures are correct. As for timing, it'll fall in the later portion of 21 and the early portion of '22. These milestones are regulatory ones tied to approvals in China and South Korea. The bigger amount, 7.5 million, is tied to the China milestone.
Michael Higgins
analystAlright, that's useful, thank you. I want to ask about the uncertainty that's going on right now with AMAG. Joe raised a good point about timing, and it does sound like this is something they're clearly working toward. There's also precedent from the past where <<inaudible>> was developed and sold, and then it came back to them. They had argued that it wasn't being marketed properly, and essentially they got the drug back and were paid for it. It was basically a settlement. Given the contract and how it's structured, is that something that could happen here if need be?
Carl Spana
executiveMike, it's Carl here. Look, let me say this again: we hold the view — and these aren't just words — that Vyleesi has enormous commercial potential. And we genuinely thought AMAG was the partner who could make that happen. Unfortunately, things didn't pan out. Right up until their divestiture, they weren't committed. The bottom line is this: we won't hand this product over to anyone we don't see as dedicated to selling it. So if that means Palatin must step into the breach and take the product back, then that's what we'll do. We see tremendous value here, and we're not afraid to take it on and grow it. I mean, it's just — ideally, of course, we'd prefer a larger company with better resources and infrastructure. But we certainly won't sit by and let this product wither. We intend to protect it.
Michael Higgins
analystOkay, so if it does come back, then your preference would be to develop your own internal sales force. So, would you do it yourself versus partnering with somebody else?
Carl Spana
executiveIt goes without saying that Steve and I have been preparing, and continue to prepare, for that possibility. Should it happen, we have what I believe is a thoroughly considered plan, and if it does come back to us, we will lay it out and execute on it, and that will include having the commercial infrastructure in place to support the product going forward and to grow it.
Michael Higgins
analystSo what I'm actually hearing is that you'd prefer to market it rather than re-partner it — is that right?
Carl Spana
executiveSo, at this point, I think we'd pull it back. We'd remarket it and really show just how great this product can be before we'd even consider whether we wanted to sell it or hold on to it.
Steve Willis
unknownMichael, this is Steve. To build on that point — you would need to handle this in sequence, correct? If bringing it back in isn't possible, if that's the situation that unfolds, with a plan to relicense it, then that strategy would have to be sequential. The approach would involve commercializing it and building up the value, demonstrating that value, and then at some future point — which might be 4 quarters or 6 quarters — that would be another possible strategic scenario to weigh. But at the outset, we would be proceeding with the product and simply providing the attention it requires in order to expand to the greatest enormous.
Michael Higgins
analystAll right, that’s clear. Thank you — that’s quite useful. I understand this: we saw no Vyleesi revenue reported in this Q even though the launch happened last fall, and clearly you have to report ahead of AMAG. So that basically forces the question — might there be a potential restatement of AMAG’s Q1 reports for Q4, meaning calendar Q4 revenue, or going forward, do you expect to keep reporting revenue with a one-quarter lag?
Carl Spana
executiveNo. What I’m saying is that even setting aside what AMAG reports, we do receive numbers each quarter. So we’re at ease with what we’ve reflected — that it won’t be — if there is a change, it won’t be large enough to justify any kind of restatement. I think you simply have to recognize and understand that, given the way AMAG has launched the product, the first script, which is a four pack, carries no charge for the consumer. That’s the strategy AMAG has put in place. They want to make sure there are no barriers for the female entering the market. Later doses remain at $99 per script. So with the launch beginning in late September, from a numbers perspective you’re really just working through the throughput. There wouldn’t be meaningful revenue because the first dose, a four-pack script, has to go through the cycle with the female. We fully expect that the first quarter will include royalties, which of course we will reflect. And as I said earlier, some of the more granular numbers around the launch — that is, the script — we would anticipate and expect AMAG will expand upon in their first quarter conference call, which I believe is scheduled for early March.
Michael Higgins
analystAll right, that's really useful. Thanks for that. I'll get back in line again. Thanks, everyone.
Operator
operatorThat brings us to the end of the question queue — there's nothing further waiting at this time.
Carl Spana
executiveThanks. I appreciate everyone joining us for the Palatin fiscal second quarter call. I’m grateful for the thoughtful questions, and I hope they helped make clearer where things stand now and where we’re headed. We’re eager to keep advancing the company. Our prospects have us very enthusiastic, and we look forward to bringing you an update next quarter. Thanks.
Operator
operatorThank you. That brings us to the end of today's teleconference, ladies and gentlemen. You're free to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.